Insider Cluster (3 insiders) ·Filed Jun 15, 2026

ANIP

ANI PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago
Insider cluster: 3 insiders, $0.5M total
Actionable Insight • Neutral

The insider sales are too small to carry informational content. Monitor for any upcoming earnings release or material corporate events that could provide context, but no immediate trading action is warranted based on this cluster alone.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
ANIP ▼ -13.90% at T+60d
NEUTRAL call ✗ call lost -13.90% · α vs SPY -14.90% · entry $83.00 → $71.46
Entry anchored
Jun 15, 03:59 PM ET
via exchange tick
T+1d
-2.99%
call -2.99% · α -1.74%
$80.52
settled 4mo ago
T+5d
-0.07%
call -0.07% · α +2.16%
$82.94
settled 3mo ago
T+20d
-2.95%
call -2.95% · α -3.15%
$80.55
settled 3mo ago
T+60d
-13.90%
call -13.90% · α -14.90%
$71.46
settled 22d ago

Price Chart

Loading chart...

Executive Summary

Three ANIP insiders (Director, CFO, and General Counsel) sold a total of $468K in open-market transactions over a 7-day window. The total represents just 0.026% of the company's $1.8B market cap — a trivial amount that is consistent with routine portfolio diversification and not indicative of material negative sentiment.

Key Financial Metrics

Direction
selling
Total Value
$468.0K
Insiders
3

Key Facts

  • Total insider sales of $468K over 7 days (June 5–12, 2026)
  • Three insiders sold: Director Thomas Haughey ($162K), CFO Stephen Carey ($265K), General Counsel Meredith Cook ($41K)
  • Sales represent 0.026% of ANIP's $1.8B market cap — well below the 0.1% materiality threshold
  • All transactions were open-market sales (code S); no 10b5-1 plan disclosure in the filing

Financial Impact

Negligible — $468K is 0.026% of market cap

insider ownership

Risk Factors

  • Insider sales could accelerate if management perceives headwinds, but current volume is routine
  • Historical model performance on ANIP shows a 43% win rate at T+20, suggesting limited predictive power from insider activity alone

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ANIP-1781563496396
21 reports for ANIP
Performance horizon
43% Hit rate 3 of 7 directional calls best @ T+60▲ +8.88%Apr 8, 2026
Filters
Rows
Reports for ANIP — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$72.11 $77.91▲ +8.04%▲ +7.23%$71.97 (−0.19%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$73.06 $71.46▼ −2.19%▼ −1.23%$71.97 (−1.49%)
Aug 24, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$74.17 $73.25▼ −1.24%▼ −1.71%$71.97 (−2.97%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$74.77 $77.32▲ +3.41%▲ +5.37%$71.97 (−3.74%)
Aug 7, 2026
8w ago
8-K
BULLISH ★ 6/10
$78.25 $76.54▼ −2.19%▼ −2.58%$71.97 (−8.03%)
Jul 16, 2026
11w ago
Court Ruling
NEUTRAL ★ 2/10
$81.92 $78.53▼ −4.14%▼ −2.47%$71.97 (−12.15%)
Jul 13, 2026
11w ago
Press Release
BULLISH ★ 6/10
$81.08 $79.20▼ −2.32%▼ −1.53%$71.97 (−11.24%)
Jun 15, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$83.00 $82.94▼ −0.07%▲ +2.16%$71.97 (−13.29%)
Jun 11, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$81.65 $80.52▼ −1.38%▼ −1.82%$71.97 (−11.86%)
May 21, 2026
19w ago
8-K
NEUTRAL ★ 3/10
$82.72 $76.71▼ −7.27%▼ −8.92%$71.97 (−13.00%)
Showing 10 of 21

US Market Status

Market Open — Closes in 2h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 15, 2026